Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 11 August 2006
Exclusive access to antibody technology
Oxford BioMedica signed an agreement in February 2001 with the French Centre for National Scientific Research and the University of Montpellier that grants exclusive access to antibody technology
The antibody technology covers the general concept of genetic delivery of antibodies for use in the treatment of a wide range of diseases including cancer It complements technology that BioMedica has developed in-house, aimed at developing gene-based products to create, in a patient, a cellular factory that produces therapeutic antibodies for the treatment of a wide range of diseases
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
Antibodies are a key component of the immune response to disease, and increasingly, pharmaceutical companies are developing therapies using externally delivered antibodies targeted at specific diseases.
Important new drugs such as Genentech/Roche's Herceptin for breast cancer and Rituxan for lymphoma, and American Home Products's Mylotarg for leukaemia are already being sold on the market, and other new products are being developed.
The new gene-based technology being developed by Oxford BioMedica is designed to circumvent some of the problems, particularly related to manufacture and delivery of antibodies, that have been associated with the development of therapeutic antibodies.
If successful, it should lead to an increase in the number of new antibody products and should be applicable in the treatment of diseases such as cancer, inflammation or infectious diseases.
Commenting on this agreement Alan Kingsman, chief executive of Oxford BioMedica said: "We are delighted to have established a link with CNRS and the University of Montpellier.
"BioMedica is already active in immunotherapy and has commercial alliances with American Home Products and Nycomed Amersham in the antibody field.
"This agreement further strengthens the company's commercial position in gene-based antibody technology.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
